Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

All told, Lilly stock still gained 33% in 2024 ... Mounjaro and Zepbound. For the fourth quarter, Lilly calls for revenue of $3.5 billion for Mounjaro and $1.9 billion for Zepbound.

The maker of weight-loss drugs Mounjaro and Zepbound said sales of the drugs grew slower than expected in the fourth quarter, along with lower-than-expected inventory of the products. Eli Lilly ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Lilly is scheduled to report its fourth-quarter and full-year 2024 results on Feb. 6. Lilly’s stock has risen 17.5% in the past year against a decrease of 1.4% for the industry. Lilly expects ...

Jan 14 (Reuters) - Eli Lilly's (LLY.N), opens new tab stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the ...